Spatiotemporally controlled delivery of biomacromolecules via injectable hydrogels for precision modulation of the tumor immune microenvironment
Open Access
- 25 December 2025
- journal article
- review article
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1)
Abstract
The pronounced heterogeneity and immunosuppressive characteristics of the tumor immune microenvironment (TIME) substantially impede the clinical efficacy oKeywords
Funding Information
- the Natural Science Foundation of China (82325029, 32171379,U22A20156, W2441022)
- the Natural Science Foundation of China (82472123)
- the Natural Science Foundation of China (82325029, 32171379,U22A20156, W2441022)
- the Bethune Medical Department of Jilin University (2022JBGS01)
- the Fundamental Research Funds for the Central Universities, JLU
- the Natural Science Foundation of Jilin Province (YDZJ202401272ZYTS)
- Jilin University First Hospital and Academician Chen Xuesi’s Team Joint Laboratory Interdisciplinary Project (2022YYGFZJC006)
- Open Project of Key Laboratory of Organ Regeneration and Transplantation of Ministry of Education (KFKTZD2206)
- National Key Research and Development Program of China (2024YFA0918600)
This publication has 279 references indexed in Scilit:
- DNA Hydrogels for Cancer Diagnosis and TherapyChemBioChem, 2024
- Photosynthetic Bacteria‐Hitchhiking 2D iMXene‐mRNA Vaccine to Enable Photo‐Immunogene Cancer TherapyAdvanced Science, 2024
- From structural design to delivery: mRNA therapeutics for cancer immunotherapyExploration, 2023
- Peptide Hydrogels as Immunomaterials and Their Use in Cancer Immunotherapy DeliveryAdvanced Healthcare Materials, 2023
- Chemokines as possible therapeutic targets in metastatic melanomaCancer Medicine, 2023
- Cytokine‐ and chemokine‐induced inflammatory colorectal tumor microenvironment: Emerging avenue for targeted therapyCancer Communications, 2022
- Machine Learning‐Driven Biomaterials EvolutionAdvanced Materials, 2021
- The EGFR‐P38 MAPK axis up‐regulates PD‐L1 through miR‐675‐5p and down‐regulates HLA‐ABC via hexokinase‐2 in hepatocellular carcinoma cellsCancer Communications, 2021
- Constrained Nanoparticles Deliver siRNA and sgRNA to T Cells In Vivo without Targeting LigandsAdvanced Materials, 2019
- Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy DrugsJAMA Network Open, 2019